CALITHERA BIOSCIENCES INC (CALA) Fundamental Analysis & Valuation

NASDAQ:CALA • US13089P5070

Current stock price

0.3651 USD
-0.04 (-10.95%)
At close:
0.3401 USD
-0.02 (-6.85%)
After Hours:

This CALA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CALA Profitability Analysis

1.1 Basic Checks

  • CALA had negative earnings in the past year.
  • In the past year CALA has reported a negative cash flow from operations.
CALA Yearly Net Income VS EBIT VS OCF VS FCFCALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • CALA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CALA Yearly ROA, ROE, ROICCALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CALA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALA Yearly Profit, Operating, Gross MarginsCALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CALA Health Analysis

2.1 Basic Checks

  • CALA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CALA has been reduced compared to 1 year ago.
  • There is no outstanding debt for CALA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CALA Yearly Shares OutstandingCALA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M
CALA Yearly Total Debt VS Total AssetsCALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

  • CALA has an Altman-Z score of -27.42. This is a bad value and indicates that CALA is not financially healthy and even has some risk of bankruptcy.
  • CALA's Altman-Z score of -27.42 is on the low side compared to the rest of the industry. CALA is outperformed by 91.98% of its industry peers.
  • CALA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.42
ROIC/WACCN/A
WACC9.19%
CALA Yearly LT Debt VS Equity VS FCFCALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

  • CALA has a Current Ratio of 3.76. This indicates that CALA is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.76, CALA is not doing good in the industry: 66.98% of the companies in the same industry are doing better.
  • A Quick Ratio of 3.76 indicates that CALA has no problem at all paying its short term obligations.
  • The Quick ratio of CALA (3.76) is worse than 65.72% of its industry peers.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.76
CALA Yearly Current Assets VS Current LiabilitesCALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CALA Growth Analysis

3.1 Past

  • CALA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.17%, which is quite impressive.
  • CALA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
  • The Revenue for CALA have been decreasing by -24.04% on average. This is quite bad
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.04%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.34% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 120.38% on average over the next years. This is a very strong growth
EPS Next Y69.34%
EPS Next 2Y38.25%
EPS Next 3Y23.9%
EPS Next 5Y14.34%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.38%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CALA Yearly Revenue VS EstimatesCALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2025 2026 2027 200M 400M 600M 800M
CALA Yearly EPS VS EstimatesCALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

1

4. CALA Valuation Analysis

4.1 Price/Earnings Ratio

  • CALA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CALA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CALA Price Earnings VS Forward Price EarningsCALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALA Per share dataCALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CALA's earnings are expected to grow with 23.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.25%
EPS Next 3Y23.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CALA Dividend Analysis

5.1 Amount

  • No dividends for CALA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CALA Fundamentals: All Metrics, Ratios and Statistics

CALITHERA BIOSCIENCES INC

NASDAQ:CALA (2/1/2023, 8:04:28 PM)

After market: 0.3401 -0.02 (-6.85%)

0.3651

-0.04 (-10.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners111.41%
Ins Owner Change0%
Market Cap1.78M
Revenue(TTM)N/A
Net Income(TTM)-83.56M
Analysts84
Price Target5.1 (1296.88%)
Short Float %0.14%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.48%
Min EPS beat(2)-2.28%
Max EPS beat(2)41.23%
EPS beat(4)3
Avg EPS beat(4)11.38%
Min EPS beat(4)-2.28%
Max EPS beat(4)41.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.12%
EPS NQ rev (1m)11.13%
EPS NQ rev (3m)11.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-205.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)-12
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-12.48
FCFYN/A
OCF(TTM)-12.45
OCFYN/A
SpS0
BVpS5.42
TBVpS5.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.76
Altman-Z -27.42
F-Score2
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)23.75%
Cap/Depr(5y)88.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33%
EPS Next Y69.34%
EPS Next 2Y38.25%
EPS Next 3Y23.9%
EPS Next 5Y14.34%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.04%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.38%
EBIT growth 1Y-50.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24%
OCF growth 3YN/A
OCF growth 5YN/A

CALITHERA BIOSCIENCES INC / CALA Fundamental Analysis FAQ

What is the fundamental rating for CALA stock?

ChartMill assigns a fundamental rating of 3 / 10 to CALA.


What is the valuation status for CALA stock?

ChartMill assigns a valuation rating of 3 / 10 to CALITHERA BIOSCIENCES INC (CALA). This can be considered as Overvalued.


Can you provide the profitability details for CALITHERA BIOSCIENCES INC?

CALITHERA BIOSCIENCES INC (CALA) has a profitability rating of 0 / 10.


How financially healthy is CALITHERA BIOSCIENCES INC?

The financial health rating of CALITHERA BIOSCIENCES INC (CALA) is 2 / 10.